Inventor
TANG XIAOLIN
US18 patents
⚠️ This page may combine multiple inventors who share the name “TANG XIAOLIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
14 patentsUS10435473B2Oct 8, 2019
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA18 citations93
US9238692B2Jan 19, 2016
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA26 citations93
US10342876B2Jul 9, 2019
Process for reducing subvisible particles in a pharmaceutical formulation
REGENERON PHARMA17 citations92
US11525629B2Dec 13, 2022
Target residual moisture content for lyophilized drug product
REGENERON PHARMA4 citations81
US11351256B2Jun 7, 2022
Room temperature stable lyophilized protein
REGENERON PHARMA9 citations81
US11926670B2Mar 12, 2024
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA1 citations72
US11059896B2Jul 13, 2021
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA3 citations72
US12066246B2Aug 20, 2024
Target residual moisture content for lyophilized drug product
REGENERON PHARMA2 citations70
US11713922B2Aug 1, 2023
Target residual moisture content for lyophilized drug product
REGENERON PHARMA3 citations70
US11241498B2Feb 8, 2022
Room temperature stable lyophilized protein
REGENERON PHARMA1 citations69
US12070502B2Aug 27, 2024
Process for reducing subvisible particles in a pharmaceutical formulation
REGENERON PHARMA0 citations60
US12449198B2Oct 21, 2025
Target residual moisture content for lyophilized drug product
REGENERON PHARMA0 citations59
US12514925B2Jan 6, 2026
Room temperature stable lyophilized protein
REGENERON PHARMA0 citations58
US12042538B2Jul 23, 2024
Methods of reducing particle formation and compositions formed thereby
REGENERON PHARMA0 citations49